Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib

Abstract Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibi...

Full description

Bibliographic Details
Main Authors: Li Huo, Jundan Xie, Qian Wang, Hongjie Shen, Zixuan Ding, Lijun Wen, Zhao Zeng, Yi Xu, Changgeng Ruan, Suning Chen, Mengxing Xue
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Clinical Case Reports
Subjects:
BCR‐ABL1 fusion gene
CALR mutation
myeloproliferative neoplasms
nilotinib
ruxolitinib
Online Access:https://doi.org/10.1002/ccr3.6801

Internet

https://doi.org/10.1002/ccr3.6801

Similar Items